medcann Pharma marks a milestone in the cannabis industry with exports of micro-propagated genetics to Europe

- *Customers in Spain and Portugal were the first to receive **micro-propagated cannabis clones from in vitro plant tissue culture techniques** - of the highest phytosanitary quality - for their medical cultivation operations.*

- *These first exports are the result of the partnership signed in 2022 with FASPLAN to promote innovation and best practices in the production of cannabis genetics using **biotechnology.***

14th of May, 2024 - medcann Pharma group, through its subsidiary in Colombia, marked another significant step in its portfolio specialization and international expansion strategy. This plan is designed to cater to the growing needs of the global cannabis industry for medical and scientific purposes and will be realized through the application of tissue culture technology for large-scale production.

Since its establishment in 2017, medcann Pharma has remained resolute in its aim to become a global leader in cannabis genetics for medical use. This commitment is evident in the extensive investments made in research and development and the strategic alliances with renowned biotechnology research and innovation centers worldwide.

This is the case of the partnership signed in 2022 with FASPLAN, which made this historic export possible. FASPLAN is a spin-off company of the University of Antioquia, expert in the in vitro propagation of various plant species through the standardization and development of biotechnological processes, and has been instrumental in this journey, bringing its expertise and knowledge to the table.

The first export to Europe of medcann's genetics in micro-propagated format went to Spain at the end of 2023, and recently, the group made a second delivery to a new client in Portugal; a global company dedicated to the manufacture and commercialization of active pharmaceutical ingredients derived from the cultivation, processing, and industrialization of cannabis.

Currently, the genetics are developing satisfactorily in their destination countries, with a successful percentage of seedlings rooting and acclimatizing, and will enter a phase of agronomic evaluation before the production of crops for commercial purposes.

For **Carlos Guzmán, CEO of the group**, combining medcann's genetic capital with FASPLAN's knowledge and experience is not just a business move. It's a step towards advancing the cannabis industry. This collaboration opens the door to new advances in producing micropropagation material that meets the most demanding international standards. It will also accelerate the processes of genetic improvement, hybridization,

stabilization, and characterization of new cannabis strains, benefiting the entire industry. *"We are proud of the team we have assembled for this collaboration. This important breakthrough demonstrates Colombia's ability to play a leading role in the global cannabis market and contribute to innovation and technological development in the sector to improve the quality of life of patients."*

Cannabis production for medicinal purposes must comply with Good Manufacturing Practices (GMP) to ensure the end user receives a high-quality pharmaceutical product.

"The national and global market requires the highest quality starting material in terms of genetic stability, production performance, and phytochemical diversity, among other factors. In addition, the capabilities added by this collaboration will allow us to supply disease-free cannabis genetics with traceability throughout the process, guaranteeing maximum homogeneity and stability, as the material is cloned using biotechnological techniques, optimal to produce pharmaceutical-grade plant material and easy to market worldwide; hence its enormous potential," says **Jorge Herrera, FASPLAN's manager.**

Today, FASPLAN has a high installed capacity for in vitro propagation, which allows it to produce 8,000,000 seedlings per year, a figure that could be multiplied by up to 3 if demand increases.

With this achievement, medcann's service portfolio becomes even more specialized in the production of its genetics using this type of biotechnology. This not only extends to the commercialization of micropropagation services for third parties, but also underlines the company's commitment to the cannabis industry, strengthening its value proposition to the market and positioning it for future success.

For more information, please contact:

Ana María Prieto

Communications Advisor

Ana.prieto@medcann.com